Speaker Lecture Titles

Partial list of confirmed speakers

First Name

Last Name

Country

Title

Johannes Attems UK THE NEUROPATHOLOGICAL DIAGNOSIS OF LEWY BODY DISEASES; AN UPDATE
Randall Bateman USA THE RELATIONSHIPS BETWEEN AMYLOID, TAU, AND NEURODEGENERATION IN ALZHEIMER’S DISEASE PATHOPHYSIOLOGY AND BIOMARKERS
Kaj Blennow Sweden UPDATE ON AMYLOID, TAU, NEURODEGENERATION AND GLIAL (ATNG) BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE
Mathew Blurton Jones USA USING HUMAN IPSC-MICROGLIA AND CHIMERIC MICE TO STUDY THE GENETICS OF ALZHEIMER’S DISEASE
Luc Buee France NANOBODIES TARGETING THE CORE OF TAU FILAMENTS
Frédéric Checler France EXOPEPTIDASES INVOLVED IN AB N-TERMINAL TRUNCATION: IDENTIFICATION, CONTRIBUTION TO AD NEUROPATHOLOGY AND BEHAVIORAL DEFECTS AND ALTERATIONS IN AD BRAINS
Don Cleveland USA THERAPEUTICALLY VIABLE GENERATION OF HIPPOCAMPAL NEURONS WITH ANTISENSE OLIGONUCLEOTIDE SUPPRESSION OF PTB
Claudio A. Cuello Canada NGF METABOLISM, ALZHEIMER’S PATHOLOGY AND PRECLINICAL BIOMARKERS
Jeffrey Cummings USA THE ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE:  UPDATE AND NEW DIRECTIONS
Bart De Strooper Belgium SPATIAL TRANSCRIPTOMICS TO ANALYZE THE PATHOLOGICAL CELLULAR NICHES IN ALZHEIMER’S DISEASE
Marc Diamond USA FUNCTIONAL GENETIC CLASSIFICATION OF ASSEMBLY STRUCTURES IN TAUOPATHIES
Rachelle Doody USA TACKLING NEURODEGENERATIVE DISEASES:  USING SYNERGIES ACROSS DISEASE AREAS TO SPEED DRUG DEVELOPMENT FOR PATIENTS
Marcus Fändrich Germany CRYO-EM STRUCTURES OF EX VIVO AND IN VITRO AMYLOID FIBRILS
Maria Teresa Ferretti Switzerland SEX AND GENDER CONSIDERATIONS IN NEURODEGENERATIVE DISEASES: SCIENTIFIC EVIDENCE, BIASES, AND OPPORTUNITIES FOR PRECISION MEDICINE
Adam Fleisher USA ADVANCEMENTS IN AD DRUG DEVELOPMENT – EVOLVING USE OF BIOMARKERS AND CLINICAL TRIAL DESIGN.
Nick Fox United Kingdom TBA
Dan Frenkel Israel METABOLIC CHANGES IN MICROGLIA AND THEIR EFFECT ON NEUROTOXICITY IN PARKINSON’S DISEASE
Giovanni Frisoni SWITZERLAND THE PROBABILISTIC AMYLOID CASCADE HYPOTHESIS OF ALZHEIMER’S DISEASE
James Galvin USA THE HEALTHY BRAIN INITIATIVE: EXAMINATION OF RESILIENCE AND VULNERABILITY FACTORS TO DISTINGUISH HEALTHY BRAIN AGING FROM NEURODEGENERATIVE DISEASE
Klaus Gerwert Germany ABETA-STRUCTURE PREDICTS CLINICAL ALZHEIMER’S 17 YEARS BEFORE CLINICAL CONVERSION
Michel Goedert UK CRYO-EM STRUCTURES OF AMYLOID FILAMENTS FROM HUMAN BRAIN
Gabriel Gold Switzerland DO VASCULAR RISK SCORES PREDICT CEREBRAL VASCULAR LESIONS?
Todd Golde USA THE AMYLOID Β PROTEIN ASSOCIATED PROTEOME YIELDS NEW TARGETS FOR ALZHEIMER’S DISEASE THERAPEUTICS
Steven Gomperts USA CARBON MONOXIDE AT LOW DOSES REDUCES DOPAMINE CELL LOSS AND ALPHA-SYNUCLEIN PATHOLOGY IN MODELS OF PARKINSON’S DISEASE
John Growdon USA DEMENTIA COMES TO PARKINSON DISEASE: MOLECULAR BASES AND HOW TO DETECT THEM
Christian Haass Germany THERAPEUTIC TARGETING OF MICROGLIAL FUNCTIONS
Harald Hampal FRANCE TBA
Michael Heneka Germany CELLULAR INTERACTIONS OF MICROGLIA IN NEURODEGENERATIVE DISEASE
Joachim Herz USA PREVENTION OF ALZHEIMER’S DISEASE BY RESTORING ENDOSOMAL TRAFFICKING
David Holtzman USA AMYLOID-INDUCED TAU SEEDING/SPREADING: ROLE OF MICROGLIA, TREM2, AND APOE
Costantino Iaedecola USA TAU MICROANGIOPATHY: FROM NETWORK DYSFUNCTION TO DISORDERED NEUROVASCULAR COUPLING
Takeshi Iwatsubo Japan ESTABLISHING TRIAL READY COHORT OF PRECLINICAL ALZHEIMER’S DISEASE IN JAPAN
Clifford Jack USA CURRENT ASSESSMENT OF IMAGING AND BIOFLUID ALZHEIMER’S BIOMARKERS
William Jagust USA TAU IN THE TEMPORAL LOBE: NEURAL ACTIVITY, MEMORY, AND AGING
Beomseok Jeon Korea VIDEO-BASED GAIT ANALYSIS
Keith Johnson USA TAU BIOMARKERS: UPDATE ON CLINICAL TRIAL DESIGNS, AND APPROPRIATE USE
Miia Kivipelto Sweden TBA
Frank Laferla USA MODELING LATE-ONSET ALZHEIMER’S DISEASE IN MICE
Virginia Lee USA TBA
Seung-Jae Lee Korea INTERPLAY BETWEEN NEUROINFLAMMATION AND AGGREGATE PROPAGATION
Eva Mandelkow Germany TREATMENTS AND REVERSAL OF TAU PATHOLOGY IN TRANSGENIC MICE
Eckhard Mandelkow Germany CELLULAR AND STRUCTURAL ASPECTS OF TAU PROTEIN AND TAU INTERACTIONS
Ken Marek USA STRATEGIES TO DEVELOP PRODROMAL BIOMARKER SIGNATURES IN PARKINSON DISEASE
Eliezer Masliah USA NOVEL IMMUNE SYSTEM THERAPEUTICAL TARGETS FOR SYNUCLEINOPATHIES OF THE AGING POPULATION
Pamela McLean USA THERAPEUTIC STRATEGIES FOR SYNUCLEINOPATHIES
Daniel M. Michaelson Israel APOE4: AN EMERGING THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE
Asuka Morizane Japan CELL REPLACEMENT THERAPY FOR PARKINSON’S DISEASE WITH IPS CELLS
John Morris USA DIAGNOSTIC ACCURACY OF THE ADNI CLINICAL DIAGNOSIS OF ALZHEIMER DISEASE:  A CLINICOPATHOLOGICAL STUDY
Henrietta Nielsen Sweden APOE BEYOND THE BRAIN
Agneta Nordberg Sweden TRANSLARTIONAL IMAGING STUDIES OF REACTIVE OF REACTIVE ASTROCYTES AT DIFFERENT STAGES OF AD- IMPLICATION FOR EARLY DIAGNOSIS AND TREATMENT
Chiba-Falek Ornit USA GENE THERAPY APPROACHES TARGETING SNCA EXPRESSION FOR PRECISION MEDICINE IN PARKINSON’S DISEASE AND RELATED DISORDERS
Tiago Outerio Germany EPIGENETIC AND EPITRANSCRIPTOMIC REGULATION OF GENE EXPRESSION IN MODELS OF PARKINSON’S DISEASE
Ronald Petersen USA CLINICAL AND BIOMARKER COMBINATIONS FOR EARLY ALZHEIMER’S DISEASE TRIALS
Marco Prado Canada CHANGES IN VESICULAR ACETYLCHOLINE TRANSPORTER (VACHT) LEVELS HAVE A CAUSAL EFFECT ON AMYLOID PATHOLOGY, COGNITIVE FUNCTION AND NEURODEGENERATION
Gill Rabinovici USA MECHANISMS UNDERLYING HETEROGENEITY IN ALZHEIMER’S DISEASE: INSIGHTS FROM PET
Laura Ranum USA EXPANDING ROLE OF MICROSATELLITE REPEATS IN NEURODEGENERATIVE DISEASE
Stephen Salloway USA CREATING PATHWAYS FOR BREAKTHROUGHS IN ALZHEIMER’S DISEASE
Philip Scheltens The Netherlands THE LONG JOURNEY OF DRUG DEVELOPMENT IN AD: HURDLES, PITFALLS AND LESSONS LEARNED
Michael Schlossmacher Canada APPLYING DR. HORNYKIEWICZ’S LEGACY: STUDYING THE HUMAN BRAIN WILL REVEAL SECRETS (AND VARIANTS) OF PARKINSON’S
Reinhold Schmidt Austria ADVANCED MR SEQUENCES FOR DETECTING STRUCTURAL ABNORMALITIES IN BRAIN AGING AND DEMENTIA
Taylor Schmitz Canada CORTICAL MAPPING OF TAU AGGREGATION AND CHOLINERGIC DENERVATION WITH MULTIMODAL POSITRON EMISSION TOMOGRAPHY
Lon Schneider USA TBA
Menahem Segal Israel PRESENILINS, OXIDATIVE STRESS AND CELL DEATH IN ANIMAL MODELS OF AD
Tamara Shiner Israel DEMENTIA WITH LEWY BODIES: IMPACT OF GBA MUTATIONS AND OTHER COMMON GENETIC FACTORS
Sam Sisodia USA IMPACT OF THE GUT MICROBIOME ON AMYLOIDOSIS AND MICROGLIAL FUNCTION
Beka Solomon Israel INHIBITION OF CXCR4/CXCL12 SIGNALING: A TRANSLATIONAL PERSPECTIVE FOR ALZHEIMER’S DISEASE TREATMENT
Reisa Sperling USA HOW EARLY DO WE NEED TO INTERVENE TO ACTUALLY PREVENT ALZHEIMER’S DEMENTIA?
Maria Grazia Spillantini UK INTERACTION BETWEEN NEURONES AND GLIAL CELLS IN NEURODEGENERATIVE DISEASES WITH PROTEIN AGGREGATION
Peter St. George-Hyslop Canada NORMAL AND PATHOLOGICAL MICROGLIAL SIGNALLING PATHWAYS
Fabrizio Stocchi Italy TREATMENT OF PARKINSON’S DISEASE: WHAT ABOUT THE NEXT FUTURE
Tom Sudhof USA REGULATION OF SYNAPTIC FUNCTION BY ALZHEIMER’S DISEASE ASSOCIATED GENES
Rudy Tanzi USA THE INNATE IMMUNE PROTECTION HYPOTHESIS OF ALZHEIMER’S DISEASE
John Trojanowski USA IMPORTANCE OF COINCIDENT NEURODEGENERATIVE DISEASE
Christine Van Broeckhoven Belgium GENETIC COMPLEXITY AND RARE VARIANTS IN NEURODEGENERATIVE BRAIN DISEASES
Robert Vassar USA THE ROLE OF DYSTROPHIC NEURITES IN ALZHEIMER’S DISEASE
Carina Wattmo SWEDEN INTERACTION EFFECT OF SEX AND ONSET OF ALZHEIMER’S DISEASE—RATES OF PROGRESSION AND PROGNOSIS
Michael Weiner USA IMPROVING GENERALIZABILITY OF AD CLINICAL TRIALS BY RECRUITING UNDER-REPRESENTED GROUPS: THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI)
Cheryl Wellington Canada TBA
Donna Wilcock USA PLASMA BIOMARKER IDENTIFICATION FOR DEMENTIA-CAUSING PATHOLOGIES IN A LONGITUDINAL AGING COHORT WITH AUTOPSY
Bengt Winblad SWEDEN NEED FOR TREATMENT WITH SMALL, COST-EFFECTIVE MOLECULES IN ALZHEIMER DISEASE
Manfred Windisch Austria CAN PRE-CLINICAL MODEL SYSTEMS HELP US TO INCREASE THE RATE OF SUCCESS OF DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE AND RELATED NEURODEGENERATIVE DISORDERS?
Tony Wyss-Coray USA A MOLECULAR SYSTEMS APPROACH TO UNDERSTAND ALZHEIMER’S DISEASE
Huaxi Xu USA THE PATHOPHYSIOLOGICAL ROLE OF MICROGLIAL APOE
Henrik Zetterberg Sweden NOVEL CSF BIOMARKERS FOR SYNAPTIC AND LYSOSOMAL FUNCTION IN NEURODEGENERATIVE DISEASES
Berislav Zlokovic USA BLOOD-BRAIN BARRIER ROLE IN NEURODEGENERATION, COGNITIVE DYSFUNCTION AND ALZHEIMER’S DISEASE